July 31 (Reuters) - Moderna ( MRNA ) plans to slash
roughly 10% of its global workforce by the end of the year to
cut costs at a time when sales of its COVID-19 vaccines are
slowing, the company said on Thursday.
"By the end of the year, we expect to be fewer than 5,000
colleagues strong," Moderna ( MRNA ) CEO Stephane Bancel said in a memo
to employees.